New immunotherapy for HPV-negative head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of head and neck cancer that is HPV-negative (p16-negative).
- Your cancer must be Stage IV or a specific Stage III (for nasopharyngeal) and has not spread to distant organs.
- You cannot have had any prior treatment (like radiation, chemo, or surgery) for this head and neck cancer.
- You must be 18 years or older and in good enough health to walk and take care of yourself (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- Your heart, liver, kidney, and blood counts must be within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests a new combination of immunotherapy drugs and an HPV vaccine alongside chemotherapy and radiation for throat cancers caused by HPV. The goal is to see if this approach works as well as standard treatment while using less radiation, potentially reducing side effects.
This trial tests a custom treatment plan for people with advanced head and neck cancer that is not caused by HPV. It combines radiation and chemotherapy with a targeted drug called cetuximab, adjusted based on your tumor's characteristics.
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.